Cambridge Investment Research Advisors Inc. Purchases 4,034 Shares of Eli Lilly and Company (NYSE:LLY)

Cambridge Investment Research Advisors Inc. boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,237 shares of the company's stock after purchasing an additional 4,034 shares during the period. Eli Lilly and Company comprises approximately 0.5% of Cambridge Investment Research Advisors Inc.'s investment portfolio, making the stock its 29th biggest position. Cambridge Investment Research Advisors Inc.'s holdings in Eli Lilly and Company were worth $134,819,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. FPC Investment Advisory Inc. increased its holdings in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares during the period. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company during the fourth quarter valued at $43,000. Prudent Man Investment Management Inc. bought a new stake in Eli Lilly and Company during the fourth quarter valued at $48,000. Highline Wealth Partners LLC boosted its position in Eli Lilly and Company by 53.3% during the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after acquiring an additional 24 shares during the last quarter. Finally, Capital A Wealth Management LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at $63,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 1.0%

Shares of LLY traded up $7.43 on Monday, reaching $770.16. The company's stock had a trading volume of 3,946,850 shares, compared to its average volume of 3,669,771. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a market capitalization of $729.91 billion, a PE ratio of 62.67, a PEG ratio of 1.11 and a beta of 0.41. The firm has a fifty day moving average of $780.81 and a 200-day moving average of $800.36.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the company earned $2.58 EPS. The company's revenue was up 45.2% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Wall Street Analyst Weigh In

A number of analysts have commented on LLY shares. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, June 7th. Guggenheim reaffirmed a "buy" rating and set a $936.00 price target on shares of Eli Lilly and Company in a research report on Friday. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,011.79.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.